FINAL PROGRAM - Imo
FINAL PROGRAM - Imo
FINAL PROGRAM - Imo
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Participant Financial Disclosure Index<br />
Participant Financial<br />
Disclosure Index<br />
Richard L Lindstrom MD<br />
3D Vision Systems; C,O<br />
Abbott Medical Optics; C<br />
AcuFocus, Inc.; C,O<br />
Alcon Laboratories, Inc.; C<br />
Bausch & Lomb Surgical; C,P<br />
BioSyntrx; C,O<br />
Calhoun Vision Inc; C,O<br />
Clarity Ophthalmics; C<br />
Clear Sight ; C,O<br />
CoDa Therapeutics ; C,O<br />
Confluence Acquisition<br />
Partners I, Inc. ; O<br />
Curveright, LLC; C<br />
EBV Partners ; C,O<br />
EGG Basket Ventures ; C,O<br />
Encore; C,O<br />
Evision; C,O<br />
Eyemaginations; C,O<br />
Foresight Venture Fund; C,O<br />
Fziomed; C,O<br />
Glaukos Corporation; C,O<br />
Healthcare Transaction<br />
Services ; O<br />
HEAVEN Fund ; O<br />
High Performance Optics ; C,O<br />
Hoya Surgical Optics; C<br />
Improve Your Vision ; C,O<br />
Ista Pharmacuticals; C<br />
LensAR, Inc.; C,O<br />
LenSX; C<br />
Life Guard Health; C,O<br />
Lumineyes,Inc.; C<br />
Minnesota Eye Consultants;<br />
C,O<br />
NuLens, Ltd.; C,O<br />
Ocular Optics; C,O<br />
Ocular Surgery News; C<br />
Ocular Therapeutix; C<br />
Omega Eye Health; C,O<br />
Omeros Corporation; C<br />
Pixel Optics; C,O<br />
Qwest; C,O,P<br />
Refractec Inc; C,O<br />
Revision Optics; O<br />
SRxA; C<br />
William Link, PhD<br />
AcuFocus, Inc.; O<br />
Glaukos Corporation; O<br />
Neurotech, Forsight, Neovista,;<br />
O<br />
Nexis Vision; O<br />
Second Sight; O<br />
WaveTec; O<br />
Isaac Lipshitz MD<br />
OptoLight Vision Technology;<br />
O,P<br />
Brian C Little MD<br />
Bausch Lomb; C,L<br />
Eyemovies Ltd; P<br />
James C Loden MD<br />
Abbott Medical Optics; C<br />
iCataract; O,P<br />
Ista Pharmacuticals; C<br />
Omerous Corporation; C<br />
Nils A Loewen MD<br />
NeoMedix Corporation; L<br />
Anat Loewenstein MD<br />
Allergan, Inc.; C,L<br />
Forsightlabs; C<br />
Lumenis, Inc.; C,L<br />
Notal Vision, Ltd.; C,<br />
Novartis Pharmaceuticals<br />
Corporation; C,L<br />
Orabio; C<br />
John I Loewenstein MD<br />
Massachusetts Eye and Ear<br />
Infirmary; P<br />
Stephanie J Loomis<br />
NIH; S<br />
Ron K Lord MD<br />
Cloud Nine Development; O<br />
Careen Yen Lowder MD PhD<br />
Allergan; C<br />
Anthony J Lubniewski MD<br />
Mid America Transplant<br />
Services Eye Bank; C<br />
Jodi I Luchs MD<br />
Alcon Laboratories, Inc.; L<br />
Allergan; C,L<br />
Bausch Lomb; C,L<br />
Eyegate Pharma; C<br />
Inspire Pharmaceuticals,<br />
Inc.; C,L<br />
NiCox; C<br />
Optimedica; C,O<br />
Brandon J Lujan MD<br />
Carl Zeiss Meditec; C,L<br />
GENENTECH; C,L<br />
Michael J Lynn<br />
National Eye Institute; S<br />
M<br />
Mathew W MacCumber MD<br />
PhD<br />
ArcticDx; S<br />
GENENTECH; C,L,S<br />
GlaxoSmithKline; S<br />
Optos, Inc.; S<br />
Regeneron; C<br />
Sequenom; S<br />
Thrombogenics; C<br />
Ian M MacDonald MD<br />
Novartis Pharmaceuticals<br />
Corporation; L<br />
Susan M MacDonald MD<br />
Alcon Laboratories, Inc.; C<br />
Scott M MacRae MD<br />
AcuFocus, Inc.; C<br />
Bausch & Lomb Surgical; C,L<br />
Technolas ; C<br />
Marian Sue Macsai-Kaplan<br />
MD<br />
Alcon Laboratories, Inc.; L<br />
Allergan, Inc.; L<br />
Bausch & Lomb Surgical; L<br />
Inspire Pharmaceuticals Inc; L<br />
STAAR Surgical; L<br />
Visiogen, Inc.; C<br />
Ted Maddess PhD<br />
Carl Zeiss Meditec; P<br />
Naoyuki Maeda MD<br />
Abbott Medical Optics; L<br />
Alcon Laboratories, Inc.; C<br />
CIBA Vision, a Novartis<br />
Company; L<br />
Johnson & Johnson; L<br />
Oculus, Inc.; L<br />
Santen, Inc.; L<br />
Tomey Corp.; L<br />
Topcon Corp; S<br />
Maureen G Maguire PhD<br />
Inspire Pharmaceuticals Inc; S<br />
Merck & Co., Inc.; C<br />
Francis S Mah MD<br />
Alcon Laboratories, Inc.; C, S<br />
Ista Pharmacuticals; C<br />
Shaam Mahasneh<br />
Society to Prevent Blindness.<br />
NY, NY; S<br />
Parag A Majmudar MD<br />
Alcon Laboratories, Inc.; C<br />
Allergan, Inc.; C<br />
Bausch & Lomb Surgical; C<br />
Ista Pharmacuticals; C,S<br />
Mobius Therapeutics; C<br />
Rapid Pathogen Screening; O<br />
Tear Science; C,S<br />
Ranjan P Malhotra MD<br />
Alcon Laboratories, Inc.; L<br />
Allergan; L<br />
Bausch Lomb; L<br />
Merck & Co., Inc.; L<br />
Andrew Maller MBA<br />
Allergan; C<br />
Bruce S Maller<br />
Allergan, Inc.; C<br />
Robert K Maloney MD<br />
Abbott Medical Optics; C,L<br />
AcuFocus, Inc.; O<br />
Calhoun Vision Inc; C,L,O<br />
Presbia Corp.; C<br />
STROMA Medical Corporation;<br />
O<br />
Boris Malyugin MD PhD<br />
Bausch Lomb; C<br />
Morcher GmbH; P<br />
MST; P<br />
Nick Mamalis MD<br />
Abbott Medical Optics; C,S<br />
Alcon Laboratories, Inc.; S<br />
Allergan; S<br />
ANew; C,S<br />
Bausch + Lomb; S<br />
Calhoun Vision Inc; S<br />
Medennium, Inc.; S<br />
NuView, Inc; S<br />
optimedica; C<br />
powervision; S<br />
Zaid Mammo, MD<br />
Pfizer, Inc.; S<br />
Edward E Manche MD<br />
Best Doctors, Inc.; C<br />
Calhoun Vision Inc; O<br />
Guidepoint; C<br />
Ophthonix, Inc.; O<br />
Seros Medical, LLC; O<br />
Michiko Mandai<br />
Novartis Pharmaceuticals<br />
Corporation; C,L<br />
Efrem D Mandelcorn, MD<br />
FRCSC<br />
Bausch Lomb; L<br />
Steven L Mansberger MD<br />
MPH<br />
Allergan; C, L<br />
Glaukos Corporation; C<br />
Merck ; S<br />
Santen, Inc.; C<br />
Sam Edward Mansour MD<br />
IRIDEX; C,L<br />
QLT Phototherapeutics, Inc; C<br />
Kaweh Mansouri MD<br />
Sensimed AG; C<br />
Anand V Mantravadi MD<br />
Allergan; L<br />
Glaukos Corporation; C<br />
John A Marasco<br />
Marasco & Associates,<br />
Healthcare Architects &<br />
Consultants; E,O<br />
Michael F Marmor MD<br />
Basilea; C<br />
Comentis; C,O<br />
Corcept; C<br />
GlaxoSmithKline; C<br />
Merck; C<br />
QLT; C<br />
ThromboGenics; C<br />
John Marshall PhD<br />
Alcon Laboratories, Inc.; C,L,O<br />
Avedro; C,L,O<br />
Ellex; L,O,P<br />
Nexisvision; C,O<br />
OPKO; C,P<br />
SCHWIND eye-tech-solutions;<br />
L<br />
John Joseph Martin, MD<br />
medicis; C<br />
Keith R Martin MD<br />
Allergan; L<br />
Samuel Masket MD<br />
Alcon Laboratories, Inc.; C,L<br />
Bausch & Lomb Surgical; L<br />
Haag-Streit; C<br />
Ocular Theraputix; C,O<br />
PowerVision; C<br />
Zeiss; L<br />
Mina Massaro-Giordano MD<br />
Daylan Sciences; O<br />
Cynthia Mattox MD FACS<br />
AHRQ; S<br />
Alcon Laboratories, Inc.; S<br />
National Eye Institute; S<br />
Transcend; S<br />
Martine Mauget-Faysse MD<br />
Novartis Pharmaceuticals<br />
Corporation; C<br />
Vincenzo Maurino MRCOPHTH<br />
Abbott Medical Optics; S<br />
Carl Zeiss Meditec; S<br />
Louise A Mawn MD<br />
NIH; S<br />
Research to Prevent Blindness;<br />
S<br />
Dennis G McCafferty, COE,<br />
MBA<br />
Visual Clinic, LLC; E,O<br />
Mary Ellen McCann MD<br />
NIH; S<br />
Colin A McCannel MD<br />
GENENTECH; S<br />
Savvient, Inc.; C,O<br />
James P McCulley, MD, FACS,<br />
FRCOPHTH<br />
Alcon Laboratories, Inc.; C<br />
Marguerite B McDonald MD<br />
Abbott Medical Optics; C<br />
Alcon Laboratories, Inc.; C<br />
Allergan, Inc.; C<br />
Bausch and Lomb Pharma; C<br />
Essilor; C<br />
FOCUS Laboratories; C<br />
Inspire Pharmaceuticals Inc; C<br />
Ista Pharmacuticals; C<br />
NexisVision; C<br />
Ocularis Pharma; C<br />
Optical Express; C<br />
Pfizer, Inc.; C<br />
Santen, Inc.; C<br />
Charles McGhee, PhD<br />
FRCOphth FRANZCO<br />
CoDa Therapeutics; O<br />
Felipe A Medeiros MD<br />
Alcon Laboratories, Inc.; C,L,S<br />
Allergan; C,L<br />
Carl Zeiss Meditec; L<br />
Jodhbir S Mehta, FRCS,<br />
FRCOPHTH<br />
Alcon Laboratories, Inc.; C<br />
Carl Zeiss Meditec; L,S<br />
UK Network Medical; P<br />
Robert F Melendez, MD MBA<br />
Alcon Laboratories, Inc.; C<br />
Jill S Melicher Larson MD<br />
Merz Pharm., Investigator,<br />
Indirect Comp; S<br />
Samir A Melki MD PhD<br />
qualsight; C<br />
Gerrit RJ Melles MD PhD<br />
DORC International, bv/Dutch<br />
Ophthalmic, USA; C<br />
Shannath Louise Merbs MD<br />
PhD<br />
National Eye Institute; S<br />
Stryker Corp/Medical Division;<br />
C<br />
Marilyn B Mets MD<br />
Astrazenica; O<br />
Johnson & Johnson Consumer<br />
& Personal Products Worldwide;<br />
O<br />
Novartis Pharmaceuticals<br />
Corporation; O<br />
Shahzad I Mian, MD<br />
Bausch + Lomb; S<br />
Marc A Michelson MD<br />
Oculus, Inc.; L<br />
William F Mieler, MD<br />
Alcon Laboratories, Inc.; C<br />
Allergan, Inc.; C<br />
GENENTECH; C<br />
Eydie G Miller-Ellis MD<br />
Alcon Laboratories, Inc.; C<br />
Allergan, Inc.; C<br />
Merck & Co., Inc.; C<br />
Joan W Miller MD<br />
Alcon Laboratories, Inc.; C<br />
Novartis Pharmaceuticals<br />
Corporation; O<br />
QLT Phototherapeutics, Inc; P<br />
Kevin M Miller MD<br />
Alcon Laboratories, Inc.; L,S<br />
Calhoun Vision Inc; S<br />
Hoya Surgical Optics; S<br />
Physical Optics Corporation; S<br />
Neil R Miller MD<br />
National Eye Institute; S<br />
Quark Pharmaceuticals; C<br />
342<br />
The presenters above have a financial interest. See page 333 for Description of Financial Interests key.
Change language